We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eagle Pharmaceuticals Inc | NASDAQ:EGRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.61 | 4.11 | 5.40 | 0 | 12:00:00 |
From May 2023 to May 2024
By Dean Seal
Eagle Pharmaceuticals said regulators have granted fast-track designation for CAL02, its non-biological bacterial virulence neutralizer and anti-infective agent that's being developed to treat severe community-acquired bacterial pneumonia as an add-on therapy.
Chief Executive Scott Tarriff said Wednesday that the designation allows it to work more closely with the U.S. Food and Drug Administration to advance the new treatment option, as it would be eligible to request a priority review of its new drug application.
The FDA has also granted a Qualified Infectious Disease Product designation for CAL02, the company said.
With that designation, Eagle expects to have eight to 10 years of regulatory exclusivity once its new drug application gets approved.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 14, 2023 07:24 ET (11:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Eagle Pharmaceuticals Chart |
1 Month Eagle Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
